Skip to main content

Advertisement

Table 2 Heart Rate and Blood Pressure Response

From: Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance

Variable Treatment Time (min) p-level
Pre 0 10 20 30
HR (beats/min) PLA 58.2 ± 9.5 60.4 ± 8.1 58.6 ± 8.5 59.6 ± 8.3 60.6 ± 8.4 0.84
PWS 55.5 ± 7.3 58.2 ± 9.5 54.2 ± 7.2 56.5 ± 7.7 58.1 ± 8.1
PWS + S 56.6 ± 7.2 57.5 ± 8.8 56.5 ± 9.5 58.4 ± 9.1 60.4 ± 10.8
SBP (mmHg) PLA 113.3 ± 7.6 114.3 ± 8.0 112.7 ± 6.8 114.3 ± 6.3 113.6 ± 6.6 0.52
PWS 111.5 ± 7.1 112.4 ± 7.3 112.9 ± 8.6 112.8 ± 7.9 112.5 ± 8.2
PWS + S 113.1 ± 7.8 112.5 ± 8.3 113.0 ± 9.6 113.9 ± 10.6 114.6 ± 10.0
DBP (mmHg) PLA 69.6 ± 6.8 69.2 ± 6.5 68.8 ± 6.3 69.5 ± 7.4 69.1 ± 7.1 0.51
PWS 69.0 ± 6.7 70.7 ± 6.1 70.9 ± 7.1 70.6 ± 7.5 70.4 ± 7.7
PWS + S 69.6 ± 7.2 70.0 ± 6.7 71.0 ± 6.8 71.1 ± 8.1 68.4 ± 13.0
  1. Data are means ± standard deviations for Heart Rate (HR), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP). MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.28), time (p = 0.03), and treatment x time (p = 0.81). Greenhouse-Geisser univariate p-levels of interactions (treatment x time) are reported above